Overview

A Study on the Use of TanakanĀ® for Recovery of Neurological Impairment Following Ischaemic Stroke

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the effectiveness of TanakanĀ® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ipsen
Treatments:
Aspirin
Criteria
Inclusion Criteria:

- Patient having had a single infarct in the carotid artery territory 3 to 8 days before
inclusion

- Patient with a moderately severe or severe disability (Modified Rankin Score 4 or 5)

- Patient having a Quick's Test (for INR) and APPT (activated partial prothrombin time)
test in the normal values of the laboratory

Exclusion Criteria:

- Patients having had an ischemic stroke (CT confirmed) less than 3 days and more than 8
days prior

- Patient with known pre-existent cerebral infarction

- Infarct damaged area bigger than 1/3 hemisphere

- Patient having a score below the cut-off point at Frenchay Aphasia Short Test